Julia Meissner
PET-guided eBEACOPP treatment of advanced-stage Hodgkin lymphoma (HD18): follow-up analysis of an international, open-label, randomised, phase 3 trial
Kreissl S, Keller U, Kühnhardt D, Ostermann H, Hertenstein B, Aulitzky W, Maschmeyer G, Vieler T, Eich H, Baues C, Stein H, Fuchs M, Diehl V, Dietlein M, Engert A, Borchmann P, Bentz M, Hitz F, Topp M, Goergen H, Buehnen I, Kobe C, Moccia A, Greil R, Eichenauer D, Zijlstra J, Markova J, Meissner J, Feuring-Buske M, Soekler M, Beck H, Willenbacher W, Ludwig W, Pabst T, German Hodgkin Study Group. PET-guided eBEACOPP treatment of advanced-stage Hodgkin lymphoma (HD18): follow-up analysis of an international, open-label, randomised, phase 3 trial. Lancet Haematol 2021; 8:e398-e409.
Jun 1, 2021PET-guided eBEACOPP treatment of advanced-stage Hodgkin lymphoma (HD18): follow-up analysis of an international, open-label, randomised, phase 3 trial
Jun 1, 2021Lancet Haematol 2021; 8:e398-e409
Kreissl Stefanie, Keller Ulrich Bernd, Kühnhardt Dagmar, Ostermann Helmut, Hertenstein Bernd, Aulitzky Walter, Maschmeyer Georg, Vieler Tom, Eich Hans, Baues Christian, Stein Harald, Fuchs Michael, Diehl Volker, Dietlein Markus, Engert Andreas, Borchmann Peter, Bentz Martin, Hitz Felicitas, Topp Max S, Goergen Helen, Buehnen Ina, Kobe Carsten, Moccia Alden, Greil Richard, Eichenauer Dennis A, Zijlstra Josée M, Markova Jana, Meissner Julia, Feuring-Buske Michaela, Soekler Martin, Beck Hans-Joachim, Willenbacher Wolfgang, Ludwig Wolf-Dieter, Pabst Thomas, German Hodgkin Study Group
PET-guided treatment in patients with advanced-stage Hodgkin's lymphoma (HD18): final results of an open-label, international, randomised phase 3 trial by the German Hodgkin Study Group
Borchmann P, Bentz M, Keller U, Kühnhardt D, Ostermann H, Schmitz N, Hertenstein B, Aulitzky W, Maschmeyer G, Vieler T, Eich H, Baues C, Stein H, Fuchs M, Kuhnert G, Diehl V, Dietlein M, Hitz F, Topp M, Goergen H, Kobe C, Lohri A, Greil R, Eichenauer D, Zijlstra J, Markova J, Meissner J, Feuring-Buske M, Hüttmann A, Dierlamm J, Soekler M, Beck H, Willenbacher W, Ludwig W, Pabst T, Engert A. PET-guided treatment in patients with advanced-stage Hodgkin's lymphoma (HD18): final results of an open-label, international, randomised phase 3 trial by the German Hodgkin Study Group. Lancet 2017; 390:2790-2802.
Oct 20, 2017PET-guided treatment in patients with advanced-stage Hodgkin's lymphoma (HD18): final results of an open-label, international, randomised phase 3 trial by the German Hodgkin Study Group
Oct 20, 2017Lancet 2017; 390:2790-2802
Borchmann Peter, Bentz Martin, Keller Ulrich Bernd, Kühnhardt Dagmar, Ostermann Helmut, Schmitz Norbert, Hertenstein Bernd, Aulitzky Walter, Maschmeyer Georg, Vieler Tom, Eich Hans, Baues Christian, Stein Harald, Fuchs Michael, Kuhnert Georg, Diehl Volker, Dietlein Markus, Hitz Felicitas, Topp Max S, Goergen Helen, Kobe Carsten, Lohri Andreas, Greil Richard, Eichenauer Dennis A, Zijlstra Josée M, Markova Jana, Meissner Julia, Feuring-Buske Michaela, Hüttmann Andreas, Dierlamm Judith, Soekler Martin, Beck Hans-Joachim, Willenbacher Wolfgang, Ludwig Wolf-Dieter, Pabst Thomas, Engert Andreas
Omission of dacarbazine or bleomycin, or both, from the ABVD regimen in treatment of early-stage favourable Hodgkin's lymphoma (GHSG HD13): an open-label, randomised, non-inferiority trial
Behringer K, Lange E, Mahlberg R, Hassler A, Vogelhuber M, Hahn D, Mezger J, Krause S, Skoetz N, Böll B, von Tresckow B, Diehl V, Hallek M, Borchmann P, Stein H, Eich H, Engert A, Bentz M, Vieler T, Kriz J, Goergen H, Tanner A, Zijlstra J, Greil R, Markova J, Sasse S, Fuchs M, Topp M, Soekler M, Mathas S, Meissner J, Wilhelm M, Koch P, Lindemann H, Schalk E, Semrau R. Omission of dacarbazine or bleomycin, or both, from the ABVD regimen in treatment of early-stage favourable Hodgkin's lymphoma (GHSG HD13): an open-label, randomised, non-inferiority trial. Lancet 2014; 385:1418-27.
Dec 22, 2014Omission of dacarbazine or bleomycin, or both, from the ABVD regimen in treatment of early-stage favourable Hodgkin's lymphoma (GHSG HD13): an open-label, randomised, non-inferiority trial
Dec 22, 2014Lancet 2014; 385:1418-27
Behringer Karolin, Lange Elisabeth, Mahlberg Rolf, Hassler Andre, Vogelhuber Martin, Hahn Dennis, Mezger Jörg, Krause Stefan W, Skoetz Nicole, Böll Boris, von Tresckow Bastian, Diehl Volker, Hallek Michael, Borchmann Peter, Stein Harald, Eich Hans, Engert Andreas, Bentz Martin, Vieler Tom, Kriz Jan, Goergen Helen, Tanner Antonia, Zijlstra Josée M, Greil Richard, Markova Jana, Sasse Stephanie, Fuchs Michael, Topp Max S, Soekler Martin, Mathas Stephan, Meissner Julia, Wilhelm Martin, Koch Peter, Lindemann Hans-Walter, Schalk Enrico, Semrau Robert
Biomarkers and peak oxygen uptake in patients with chronic lung disease
Maeder M, Bergmann A, Morgenthaler N, Staub D, Meissner J, Reiter M, Socrates T, Arenja N, Brutsche M, Mueller C. Biomarkers and peak oxygen uptake in patients with chronic lung disease. Respiration 2010; 80:543-52.
Jul 17, 2010Biomarkers and peak oxygen uptake in patients with chronic lung disease
Jul 17, 2010Respiration 2010; 80:543-52
Maeder Micha, Bergmann Andreas, Morgenthaler Nils G, Staub Daniel, Meissner Julia, Reiter Miriam, Socrates Thenral, Arenja Nisha, Brutsche Martin, Mueller Christian
Copeptin response to clinical maximal exercise tests
Maeder M, Struck J, Bergmann A, Morgenthaler N, Meissner J, Reiter M, Socrates T, Arenja N, Brutsche M, Staub D, Mueller C. Copeptin response to clinical maximal exercise tests. Clin Chem 2010; 56:674-6.
Apr 1, 2010Copeptin response to clinical maximal exercise tests
Apr 1, 2010Clin Chem 2010; 56:674-6
Maeder Micha, Struck Joachim, Bergmann Andreas, Morgenthaler Nils G, Meissner Julia, Reiter Miriam, Socrates Thenral, Arenja Nisha, Brutsche Martin, Staub Daniel, Mueller Christian